{
  "ticker": "AXE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968859",
  "id": "02968859",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0827",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrq1tt9h7cqw.pdf",
  "summary": "### Quarterly Report (Appendix 4C) Summary:  \n\n#### **Key Operational/Financial Highlights**:  \n- **Quantum Computing (12CQ project)**: Extended collaboration with Queen Mary University of London (QMUL) to advance qubit development, targeting demonstration by 1HCY26.  \n- **Biochip Progress**:  \n  - Partnered with Paragraf to enhance graphene field-effect transistor (gFET) accuracy for blood testing (focus: chronic kidney disease).  \n  - Developed integrated silicon chip combining gFET with readout circuitry, a step toward handheld diagnostic devices.  \n- **Advisory Committee**: Established with industry experts to support R&D and commercialization.  \n\n#### **Financials**:  \n- **Cash Balance (30 June 2025)**: **$13.7 million** (no debt).  \n- **Investments**:  \n  - 1,633,944 shares in Volatus Capital Corp (CSE:VC).  \n  - 10,397,806 shares + 2,892,780 options in ChemX Materials Ltd (ASX:CMX).  \n- **Quarterly Cash Burn**: Net operating cash outflow of **$1.77m**; estimated funding runway: **~7.7 quarters**.  \n\n#### **Material Developments**:  \n- IP ownership retained in all collaborations (QMUL, Paragraf).  \n- No new capital raised or material changes to capital structure.  \n\n*Omitted: Routine corporate updates, director bios, non-material partnerships.*",
  "usage": {
    "prompt_tokens": 5162,
    "completion_tokens": 307,
    "total_tokens": 5469,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T22:48:16.956673"
}